409353-42-0

Basic information

• Product Name: 3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID
• Synonyms: ASISCHEM R26696;3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID;3-(3-FORMYL-2,5-DIMETHYL-1H-PYRROL-1-YL)-BENZOIC ACID;BENZOIC ACID, 3-(3-FORMYL-2,5-DIMETHYL-1H-PYRROL-1-YL)-
• CAS NO: 409353-42-0
• Molecular Formula: C14H13NO3
• Molecular Weight: 243.26
• Mol File: 409353-42-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID(409353-42-0)
• EPA Substance Registry System: 3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID(409353-42-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 409353-42-0(Hazardous Substances Data)

Usage

General Description

3-(3-Formyl-2,5-dimethyl-pyrrol-1-yl)-benzoic acid is a chemical compound with the molecular formula C15H15NO3. It is a derivative of pyrrole and benzoic acid, containing a pyrrole ring with a formyl group and two methyl groups attached, as well as a benzoic acid group. 3-(3-FORMYL-2,5-DIMETHYL-PYRROL-1-YL)-BENZOIC ACID has potential applications in medicinal chemistry and pharmaceutical research due to its unique structure and potential biological activities. It may be used as a building block for the synthesis of novel organic compounds or as a starting material for the development of new drugs. Further studies and research are needed to fully understand the properties and potential uses of 3-(3-formyl-2,5-dimethyl-pyrrol-1-yl)-benzoic acid.

Upstream product

• 26180-28-9 3-(2,5-dimethylpyrrol-1-yl)benzoic acid 
• 68-12-2 N,N-dimethyl-formamide 

Relevant articles and documents

Small molecule fusion inhibitors: Design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3- carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41

By a scaffold elongation strategy, a series of (Z)-3-(5-(3-benzyl-4-oxo-2- thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2, 5-dimethylpyrroles and related derivatives with a linear multi-aromatic-ring skeleton were designed, synthesized, and evaluated in HIV-1 gp41 and cellular assays. Among them, the most active compounds, 12e, 12g, and 12k with a one-carbon linker (n = 1) between the rhodanine (C) and phenyl (D) rings, exhibited very promising inhibitory potency with IC50 values of 1.8-2.6 μM and EC50 values of 0.3-1.5 μM against gp41 6-HB formation and HIV-1 replication in MT-2 cells, respectively. Additionally, they were almost equally effective against both T20-sensitive and resistant strains. The related SAR studies and molecular modeling results provided potential for further developing a new class of non-peptide small molecular fusion inhibitors targeting the HIV-1 gp41.